Is 'GOLD' standard for the management of COPD in clinical practice?

Drugs in Context

Volumn , Issue , 2012, Pages

  Yawn, Barbara P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chronic bronchitis; COPD; Emphysema; Exacerbations; FEV1; Formoterol; FVC; GOLD; Immunization; Indacaterol; LABA; LAMA; LTRA; Methylxanthines; Respimat; Roflumilast; SGRQ; Tiotropium; TORCH; UPLIFT

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; INDACATEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE INHIBITOR; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ANTICHOLINERGIC EFFECT; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; FORCED VITAL CAPACITY; GOLD STANDARD; HUMAN; IMMUNIZATION; OXYGEN THERAPY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 84873586342     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212243     Document Type: Review

References (126)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD, 2011. Available at: www.goldcopd.org. [Last accessed: 19 October 2012].
2. Center for Disease Control and Prevention. Deaths: preliminary data for 2009. National Vital Statistics Reports 2011:59:4. Available at: www.cdc.gov/nchs/nvss.htm. [Last accessed: 19 October 2012].
3. World Health Organization. Chronic respiratory diseases. Chronic obstructive pulmonary disease 2011. Available at: who.int/respiratory/copd/en/. [Last accessed: 19 October 2012].
4. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:180-4.
5. O'Donnell DE Dynamic lung hyperinflation and its clinical implication in COPD. Rev Mal Respir 2008;25:1305-18.
6. Yawn B. Differential assessment and management of asthmas vs. chronic obstructive pulmonary disease. Medscape J Med 2009;11:20.
7. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12.
8. Friedlander AL, Lynch D, Dyar LA, Bowler RP. COPD phenotypes of chronic obstructive pulmonary disease. COPD 2007;2:45-68.
9. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2009;136(5Suppl):e30.
10. Yawn BP, Wollan PC. Knowledge and attitudes of family physicians coming to COPD continuing medical education. Int J Chron Obstruct Pulmon Dis 2008;3:311-17.
11. Celli B, Cross S, Grossman R et al. Improving the care of COPD patients - suggested action points by the COPD exacerbations taskforce for reducing the burden of exacerbations of COPD. Prim Care Respir J 2006;15:139-42.
12. Krowka MJ. Breathing Easier: Early Identification of COPD and Alpha-1 Antitrypsin Deficiency. Available at: http://www.medscape.org/viewarticle/726819 [Last accessed: 31 October 2012].
13. Hurst JR, Donaldson GC, Quint JK et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:369-74.
14. Miravitlles M, Andreu I, Romero Y, Sitjar S, Alt A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract 2012;62:e68-e75.
15. Kim TB, Oh YM, Chang YS et al. The reality of an intermediate type between asthma and COPD in practice. Respir Care 2012;57:1248-53.
16. Qaseem A, Wilt TJ, Weinberger SE et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155(3):179-91.
17. Jones PW, Mahler DA, Gale R, Owen R, Kramer B. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med 2011;105:892-9.
18. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
19. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
20. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011(3):CD008532.
21. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;22;356:775-89.
22. Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
23. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-8.
24. Norris SL, Yen PY, Dana TL, Care BR, Burda BU. Drug class review: beta2-agonists. Oregon Health and Science University, Portland, 2006.
25. Calverley PM. New options for bronchodilator treatment in COPD. Thorax 2010;65:468-9.
26. Hanania NA, Sharafkhaneh A, Celli B et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011;12:6.
27. O'Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol 2008;105:753-5.
28. Brienza NS, Amor-Carro O, Ramos-Barbon D: An update on the use of indacaterol in patients with COPD. Ther Adv Respir Dis 2011;5:29-40.
29. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008;133:1079-87.
30. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010;11:149.
31. Allen and Hanburys Limited. Serevent Accuhaler, Serevent Diskus, Serevent Evohaler. Summary of product characteristics. Available at: www.medicines.org.uk/EMC/searchresults.aspx?term=serevent. [Last accessed: 19 October 2012.
32. Novartis Pharmaceuticals UK Limited. Foradil: summary of product characteristics. Available at: www.medicines.org.uk/EMC/searchresults.aspx?term= foradil. [Last accessed: 19 October 2012].
33. Novartis Pharmaceuticals UK Limited. Onbrez Breezhaler 150 and 300 microgram inhalation powder, hard capsules. UK Summary of Product Characteristics. Available at: www.medicines.org.uk/EMC/searchresults.aspx?term= onbrez. [Last accessed: 19 October 2012].
34. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92.
35. Yawn B, Kleerup E, Zhang J, Kianifard F, Williams J. Inhaled corticosteroid use and GOLD severity stage among patients with chronic obstructive pulmonary disease in different regions. Am J Respir Crit Care Med 2012 [in press].
36. Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. The risks and benefits of indacaterol - the FDA's review. N Engl J Med 2011;365:2247-9.
37. FDA approved drug products: Arcapter Neohaler (indacaterol maleate). Food and Drug Administration, Silver Spring. Available at: www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/022383Orig1s000SumR.pdf. [Last accessed: 19 October 2012].
38. Human medicines: Onbrez Breezhaler (indacaterol). European Medicine Agency, London. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/001114/human-med-001219.jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d124. [Last accessed: 19 October 2012].
39. Cope S, Capkun-Niggli G, Gale R et al. Efficacy of oncedaily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health 2012;15:524-33.
40. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011;105:719-26.
41. Cave AC, Hurst MM. The use of long acting b2-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Pharmacol Ther 2011;130:114-43.
42. Wilchesky M, Ernst P, Brophy JM, Platt R, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD. Parts 1 and 2. Chest 2012;142-298-309.
43. No authors listed. Indacaterol. A long-acting beta-2 agonist, no advantages in COPD. Prescrire Int 2011; 20:201-5.
44. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105:571-9.
45. Casaburi R, Mahler DA, Jones PW et al. A longterm evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;1:217-24.
46. Celli B, ZuWallack R, Wang S et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-8.
47. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-48.
48. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58: 399-404.
49. Tashkin D, Celli B, Kesten S, Lystig T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med 2010;104:1495-504.
50. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-955.
51. Sethi S, Cote C. Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease. Curr Clin Pharmacol 2011;6:48-61.
52. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004;1:345-51.
53. Rennard SI. Combination bronchodilator therapy in COPD. Chest 1995;107(5 Suppl):171S-175S.
54. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101-8.
55. Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med 2012;106:319-28.
56. Drakatos P, Lykouras D, Sampsonas F, Karkoulias K, Spiropoulos K. Targeting leukotrienes for the treatment of COPD? Inflamm Allergy Drug Targets 2009;8:297-306.
57. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010;137:1338-44.
58. Zhang WH, Zhang Y, Cui YY et al. Can Beta2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD? Fundam Clin Pharmacol 2012; 26:118-34.
59. Voduc N, Alvarez GG, Amjadi K, Tessier C, Sabri E, Aaron SD. Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot study. Int J Chron Obstruct Pulmon Dis 2012;7:245-52.
60. Zhang J, Feng MX, Qu JM. Low dose theophylline showed an inhibitory effect on the production of IL-6 and IL-8 in primary lung fibroblast from patients with COPD. Mediators Inflamm 2012:492901.
61. Hatzelmann A, Morcillo E, Lungarella G et al. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010;23;235-56.
62. Calverley P, Rabe K, Goehring U-M et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94.
63. Fabbri L, Calverley P, Izquierdo-Alonso J et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695-703.
64. Rabe K. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Brit J Pharmacol 2011;163:53-67.
65. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001;108:671-80.
66. Compton C, Gubb J, Nieman R et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358:265-70.
67. Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 2005;11:129-34.
68. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 2002;121:192S-196S.
69. Mata M, Sarria B, Buenestado A et al. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-52.
70. Profita M, Chiappara G, Mirabella F et al. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003;58:573-9.
71. Pullen E. Roflumilast: How Much is it Worth to Avoid an Exacerbation of Chronic Bronchitis? Available at: http://drpullen.com/roflumilast [Last accessed: 31 October 2012].
72. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
73. Seemungal TA, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
74. Soler-Cataluña JJ, Martinez-Garcia M., Rom Sánchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
75. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
76. Ai-Ping C, Lee KH, Lim TK. In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest 2005;128:518-24.
77. Patil SP, Krishnan JA, Lechtzin N, Diette GB. Inhospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003;163:1180-6.
78. Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-21.
79. Burgel PR, Nesme-Meyer P, Chanez P et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009;135:975-82.
80. Wan ES, DeMeo DL, Hersh CP et al. Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir Med 2011;105:588-94.
81. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
82. American Thoracic Society, European Respiratory Society. Standards for the diagnosis and management of patients with COPD. New York/Lausanne. 20 October 2011. Available at: www.copd-ats-ers.org/copddoc.pdf. [Last accessed: 19 October 2012].
83. Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-38.
84. Donaldson GC, Wedzicha JA. COPD exacerbations.1: epidemiology. Thorax 2006;61:164-8.
85. Roy A, Wisnivesky JP. Comprehensive use of environmental control practices among adults with asthma and COPD. Allergy Asthma Proc 2010;31:72-7.
86. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. N Engl J Med 2011;364:1093-1103.
87. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-16 [Erratum in: JAMA 2009;11;301:1024].
88. Asche CV, Brixner DI, Conoscenti CS, Young DC, Shah H, Phillips A. Assessment of physician prescribing for primary care patients with chronic obstructive pulmonary disease (COPD) in a national electronic medical record (EMR) research database. Chest 2006;130:supplement 175S [abstract].
89. Bourbeau J, Sebaldt RJ, Day A et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 2008;15:13-19.
90. de Miguel-Díez J, Carrasco-Garrido P, Rejas-Gutierrez J et al. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung 2011;189:199-206.
91. Cazzola M, Segreti A, Bettoncelli G et al. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J 2011;20:291-8.
92. Mehuys E, Boussery K, Adriaens E et al. COPD management in primary care: an observational, community pharmacy-based study. Ann Pharmacother 2010;44:257-66.
93. Smith CJ, Gribbin J, Challen KB, Hubbard RB. The impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UK. QJM 2008;101:145-53.
94. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;5:189-95.
95. Patel AR, Hurst Jr. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011;5:647-62.
96. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9.
97. Wedzicha JA, Calverley PM, Seemungal TA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
98. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6.
99. Crim C, Calverley PM, Anderson JA et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7.
100. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010;104:246-52.
101. Chen S, Plauschinat CA, Wu N, Fraser K, Boulanger L. Economic impact of using inhaled corticosteroids without prior exacerbation among elderly patients with chronic obstructive pulmonary disorder. J Med Econ 2011;14:458-62.
102. Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 2012;37:204-11.
103. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335-71.
104. Melani AS, Bonavia M, Cilenti V et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8.
105. Rootmensen GN, van Keimpema AR, Jansen HM, de Haan RJ. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv 2010;23:323-8.
106. Nikander K. Challenges and opportunities in respiratory drug delivery devices. Expert Opin Drug Deliv 2010;7:1235-8.
107. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831-8.
108. Hodder R, Price D, Schulte M et al. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis 2009;4:381-90.
109. Chapman KR, Voshaar TH, Virchow JC. Inhaler choice in primary practice. Eur Respir Rev 2005;14:117-22.
110. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16:249-54.
111. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005;50:1360-74.
112. Yawn BP. Optimizing chronic obstructive pulmonary disease management in primary care. South Med J 2011;104:121-7.
113. Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006;1:251-9.
114. Dalby RN, Eicher J, Zierenberg B. Development of Respimat Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Available at: http://www.dovepress.com/development-of-respimatreg-soft-misttrade-inhaler- and-its-clinical-uti-peer-reviewed-article-MDER [Last accessed: 31 October 2012].
115. CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012-2013 influenza season. MMWR Wkly Rep 2012;61:613-618.
116. Poland G. A global prescription for adult immunization: time is catching up with us. Vaccine 2010;28: 7137-9.
117. CDC. Final state-level influenza vaccination coverage estimates for the 2010-2011 season - United States, National Immunization Survey and Behavioral Risk Factor Surveillance System, August 2010 through May 2011. Available at: www.cdc.gov/flu/professionals/vaccination/coverage-1011estimates.htm. [Last accessed: 19 October 2012].
118. CDC. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Wkly Rep 2012;21:394-5.
119. Accessed at: http://www.cdc.gov/vaccines/vpd-vac/pneumo/in-short-both. htm#who [Last accessed: 13 November 2012].
120. CDC. Pertussis (whooping cough). Accessed at: www.cdc.gov/pertussis/ index.html. [Last accessed: 19 October 2012].
121. Burns N. COPD and pulmonary rehabilitation. Aust Fam Physician 2012;41:460.
122. Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127:809-17
123. Gill, Rous R. Long-term oxygen therapy: are we prescribing appropriately? Int J Chron Obstruct Pulmon Dis 2008;3:231-7.
124. Boersma WG. Antibiotics in acute exacerbations of COPD: the good, the bad and the ugly. Eur Respir J 2012;40:1-3.
125. Hogg JC, Chu FS, Tan WC et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007;176:454-9.
126. van der Molen T, Willemse BWM, Schokker S, ten Hacken N, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13.